OSTERTAG ERIC (Chief Executive Officer) purchased 20.5% of their position (142.86K shares) of POSEIDA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $500.0K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/10/2022ACC: 0001209191-22-045296
DirectorOfficer10% Owner· Chief Executive Officer
Since Jul 2020
+142.86K
Net shares
Net buyer
$500.0K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
142.86K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+142.86K
Price / share
$3.50
Trade value
$500K
% of position
20.5%
8/8/2022
695.97K→838.82K
Total
Net shares
+142.86K
Net value
$500K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/8/2022 | P · Purchase | +142.86K | $3.50 | $500K | 20.5% | 695.97K | 838.82K |
| Total | +142.86K | $500K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)4
Common Stock
IndirectShares owned580.29K
Common Stock
IndirectShares owned3.66M
Common Stock
IndirectShares owned3.36M
Common Stock
IndirectShares owned961.45K
Total
8.56M indirect8.56M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 580.29K | Indirect |
| Common Stock | 3.66M | Indirect |
| Common Stock | 3.36M | Indirect |
| Common Stock | 961.45K | Indirect |
| Total | 8.56M | 8.56M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported